Strategic partnership Cygnus Technologies formed a strategic partnership with Dyadic International to quantify Host Cell Proteins from C1-cells, signaling potential joint service models and expanded capabilities that sales teams can leverage to cross-sell HCP analysis and related bioprocess impurity assays.

HCP ELISA expansion The launch of the C1 HCP ELISA Assay together with the Dyadic partnership indicates a growing market demand for robust HCP detection solutions, presenting a cross-sell opportunity to offer complementary immunoassays, assay development, and outsourcing services.

Award credibility Receiving the 2023 R&D 100 Award enhances credibility and can be used in outreach to larger CDMOs and biopharma manufacturers, supporting value-based pitches for upgrading or validating bioprocess quality control workflows.

Maravai ecosystem As part of Maravai LifeSciences, Cygnus sits within a broader ecosystem of assay and services, presenting opportunities to bundle offerings with related Maravai brands and to target customers already using Maravai platforms and distribution channels.

Growth through collaboration Past and ongoing collaborations with industry players like Gyros Protein Technologies and Carahsoft demonstrate a track record of partner-driven innovation, suggesting a sales strategy focused on channel partnerships and co-developed solutions for biomanufacturing QA and HCP analytics.